What question did this study set out to answer?

The aim is to evaluate the effectiveness of trastuzumab deruxtecan as a second-line treatment for metastatic ERBB2-altered non-small cell lung cancer after immunotherapy.

March 21, 2026Open Access

209eP Real-world experience with trastuzumab deruxtecan in metastatic ERBB2-altered non-small cell lung cancer

Key Points

The aim is to evaluate the effectiveness of trastuzumab deruxtecan as a second-line treatment for metastatic ERBB2-altered non-small cell lung cancer after immunotherapy.
Analyzed patient outcomes after treatment with trastuzumab deruxtecan
Included patients who had progressed after first-line immune checkpoint inhibitors
Focus on real-world effectiveness and treatment strategies
No significant differences in treatment effectiveness observed based on treatment strategies
Trastuzumab deruxtecan provides a potential option for patients after ICI progression

Abstract

second-line therapy in patients after progression of first-line ICIs therapy does not show significant differences due to the type of treatment strategies.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Ganatra et al. (Tue,) studied this question.

synapsesocial.com/papers/69be34af6e48c4981c672c8a https://doi.org/https://doi.org/10.1016/j.esmoop.2026.106516

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Demander à l'IA

Bookmark

View Full Paper